Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE ...

The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to enhance antitumor responses while minimizing liver toxicity by focusing activation within the tumor ...

Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose. This is an ASCO Meeting Abstract ...

To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal ...